Verrica Pharmaceuticals (VRCA) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue was $5.2 million, with $4.9 million from YCANTH, reflecting growing demand, expanded distribution, and a one-time specialty distributor stock-in order.

• YCANTH launched in August 2023 as the first FDA-approved treatment for molluscum contagiosum, with commercial sales beginning in Q3 2023.

• Positive Phase 2 data for VP-315 in basal cell carcinoma showed 51% complete clearance and strong safety, positioning it as a potential first-line, non-surgical therapy.

• Litigation settlement led to removal of compounded cantharidin from the US market, expected to boost YCANTH demand as inventory depletes.

• Amended agreement with Torii to co-fund global Phase 3 trial for YCANTH in common warts, with trial start expected in H1 2025.

Financial highlights

• Q2 2024 total revenue: $5.2M (product: $4.9M, collaboration: $0.3M); gross margin: 93% due to previously expensed inventory.

• Q2 2024 net loss: $17.2M ($0.37/share); non-GAAP net loss: $14.4M ($0.31/share), both higher than prior year.

• Q2 2024 SG&A expenses: $16.5M (up $10.6M YoY); R&D: $3.3M (down $2.4M YoY).

• Cash and equivalents totaled $31.9M as of June 30, 2024, expected to fund operations into Q1 2025.

• Accounts receivable increased to $10.0M; accumulated deficit reached $268.0M.

Outlook and guidance

• Expect continued aggressive YCANTH demand growth in 2H 2024 as compounded cantharidin inventory depletes.

• No revenue guidance for the remainder of 2024; long-term guidance may be considered closer to 2025.

• Global Phase 3 trial for YCANTH in common warts to begin in H1 2025, pending FDA and PMDA feedback.

• Gross margins expected to normalize in the low 90s% in 2H 2024 and beyond.

• Cash on hand expected to support operations only into Q1 2025; additional financing is required.